董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dow R. Wilson | 男 | Director,President and CEO | 62 | 980.30万美元 | 39.69 | 2021-02-01 |
| Phillip Febbo | 男 | Independent Director | 54 | 36.27万美元 | 未持股 | 2021-02-01 |
| Jean Luc Butel | 男 | Independent Director | 64 | 30.77万美元 | 0.19 | 2021-02-01 |
| Jeffrey R. Balser | -- | Independent Director | 59 | 28.69万美元 | 未持股 | 2021-02-01 |
| Anat Ashkenazi | -- | Independent Director | 48 | 未披露 | 未持股 | 2021-02-01 |
| Phillip Febbo | -- | Independent Director | 54 | 未披露 | 未持股 | 2021-02-01 |
| Michelle M. Le Beau | -- | Independent Director | 66 | 30.28万美元 | 未持股 | 2021-02-01 |
| Anat Ashkenazi | 女 | Independent Director | 48 | 29.54万美元 | 未持股 | 2021-02-01 |
| Judy Bruner | 女 | Independent Director | 62 | 31.15万美元 | 0.29 | 2021-02-01 |
| R. Andrew Eckert | 男 | Independent Director | 60 | 42.94万美元 | 2.52 | 2021-02-01 |
| David J. Illingworth | 男 | Independent Director | 67 | 29.15万美元 | 1.71 | 2021-02-01 |
| Regina E. Dugan | 女 | Independent Director | 57 | 30.00万美元 | 0.85 | 2021-02-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dow R. Wilson | 男 | Director,President and CEO | 62 | 980.30万美元 | 39.69 | 2021-02-01 |
| Christopher A. Toth | 男 | President and Chief Operating Officer | 45 | 504.18万美元 | 未持股 | 2021-02-01 |
| J. Michael Bruff | 男 | Senior Vice President, Chief Financial Officer | 55 | 243.99万美元 | 未持股 | 2021-02-01 |
| Kevin O'Reilly | 男 | Senior Vice President and President, Oncology Systems | 55 | 未披露 | 未持股 | 2021-02-01 |
| Michael Hutchinson | 男 | Senior Vice President, Chief Legal Officer and Corporate Secretary | 53 | 229.72万美元 | 未持股 | 2021-02-01 |
| Kolleen T. Kennedy | 女 | President, Proton Solutions and Chief Growth Officer | 65 | 352.20万美元 | 5.29 | 2021-02-01 |
董事简历
中英对照 | 中文 | 英文- Dow R. Wilson
-
Dow R. Wilson，自2012年9月起担任瓦里安医疗系统公司董事，自2012年9月起担任总裁兼首席执行官。2011年10月至2012年9月担任执行副总裁兼首席营运官，2005年8月至2011年9月担任公司负责肿瘤系统的执行副总裁和总裁。2005年1月至2005年8月，担任公司负责肿瘤系统的副总裁和总裁。2005年1月加入瓦里安医疗系统公司之前，曾在通用电气（一家多元化的工业公司）中担任高级管理职务。是萨巴软件公司（电子学习软件供应商）的董事会成员。
Dow R. Wilson,was appointed to serve on the Board of Directors of Siemens Healthineers AG in February 2023. He retired as President and Chief Executive Officer of Varian Medical Systems, Inc. in April 2021, a position he held since September 2012. Prior to that, Mr. Wilson served in various capacities with Varian, including Executive Vice President and Chief Operating Officer from October 2011 to September 2012 and Vice President Varian Medical and President of Varian Medical Oncology Systems business from January 2005 to September 2011. Prior to joining Varian Medical in 2005, Mr. Wilson held various senior management positions with GE Healthcare, a diversified industrial company. - Dow R. Wilson，自2012年9月起担任瓦里安医疗系统公司董事，自2012年9月起担任总裁兼首席执行官。2011年10月至2012年9月担任执行副总裁兼首席营运官，2005年8月至2011年9月担任公司负责肿瘤系统的执行副总裁和总裁。2005年1月至2005年8月，担任公司负责肿瘤系统的副总裁和总裁。2005年1月加入瓦里安医疗系统公司之前，曾在通用电气（一家多元化的工业公司）中担任高级管理职务。是萨巴软件公司（电子学习软件供应商）的董事会成员。
- Dow R. Wilson,was appointed to serve on the Board of Directors of Siemens Healthineers AG in February 2023. He retired as President and Chief Executive Officer of Varian Medical Systems, Inc. in April 2021, a position he held since September 2012. Prior to that, Mr. Wilson served in various capacities with Varian, including Executive Vice President and Chief Operating Officer from October 2011 to September 2012 and Vice President Varian Medical and President of Varian Medical Oncology Systems business from January 2005 to September 2011. Prior to joining Varian Medical in 2005, Mr. Wilson held various senior management positions with GE Healthcare, a diversified industrial company.
- Phillip Febbo
-
Phillip Febbo，Il Illumina，Inc.首席医疗官（2018年3月至今）。自2013年8月起担任Genomic Health, Inc.首席医疗官。2010年7月至2013年8月，Febbo博士曾担任旧金山University of California应用基因学的董事。而在UCSF，Febbo博士是UCSF Helen Diller家庭综合癌症中心前列腺癌计划的联席负责人和肿瘤临床试验转化研究计划的联盟计划首席研究员。2004年9月至2010年6月，Febbo博士担任Duke University医学中心协会的分子遗传学和微生物学基因的副教授。 Febbo博士持有 Dartmouth College 生物学的学士学位和旧金山 University of California的医学博士，获得了布莱根妇女医院的内科住院医师。
Phillip Febbo, M.D., has served as our Chief Medical Officer since August 2013. From July 2010 to August 2013 Dr. Febbo served as Director of Applied Genomics at the University of California, San Francisco. While at UCSF, Dr. Febbo was the Co-Leader of the Prostate Cancer Program at the UCSF Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. From September 2004 to June 2010 Dr. Febbo served as Associate Professor of Medicine and Molecular Genetics and Microbiology at Duke University Medical Center's Institute of Genome Sciences and Policy. Dr. Febbo holds a B.A. in Biology from Dartmouth College and an M.D. from the University of California, San Francisco, and completed his internal medicine residency at the Brigham and Women's Hospital. - Phillip Febbo，Il Illumina，Inc.首席医疗官（2018年3月至今）。自2013年8月起担任Genomic Health, Inc.首席医疗官。2010年7月至2013年8月，Febbo博士曾担任旧金山University of California应用基因学的董事。而在UCSF，Febbo博士是UCSF Helen Diller家庭综合癌症中心前列腺癌计划的联席负责人和肿瘤临床试验转化研究计划的联盟计划首席研究员。2004年9月至2010年6月，Febbo博士担任Duke University医学中心协会的分子遗传学和微生物学基因的副教授。 Febbo博士持有 Dartmouth College 生物学的学士学位和旧金山 University of California的医学博士，获得了布莱根妇女医院的内科住院医师。
- Phillip Febbo, M.D., has served as our Chief Medical Officer since August 2013. From July 2010 to August 2013 Dr. Febbo served as Director of Applied Genomics at the University of California, San Francisco. While at UCSF, Dr. Febbo was the Co-Leader of the Prostate Cancer Program at the UCSF Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. From September 2004 to June 2010 Dr. Febbo served as Associate Professor of Medicine and Molecular Genetics and Microbiology at Duke University Medical Center's Institute of Genome Sciences and Policy. Dr. Febbo holds a B.A. in Biology from Dartmouth College and an M.D. from the University of California, San Francisco, and completed his internal medicine residency at the Brigham and Women's Hospital.
- Jean Luc Butel
-
Jean Luc Butel，2016年6月至2019年6月担任Takeda的外部董事和审计和监督委员会成员。他于2019年6月被任命为外部董事，不是Takeda的审计和监督委员会成员。他有提供肾脏和医院产品组合的医疗保健公司百特国际公司的职位：国际总裁（2015年1月至2015年6月）；公司运营总监，公司副总裁兼国际总裁（2012年2月） （2014年12月）。医疗技术领域的全球领导者美敦力公司的职位：公司官员，执行委员会成员，执行副总裁；国际集团总裁（2011年1月至2012年1月）；美敦力国际公司执行官，执行委员会委员，高级副总裁兼总裁（2008年5月至2010年12月）；美敦力公司行政总监，执行委员会委员，高级副总裁兼总裁亚太地区（2003年8月至2008年4月）。他在加入美敦力公司之前，在1991年到1999年担任过迪金森公司各种各样的领导角色后，担任独立技术、强生公司总裁。
Jean Luc Butel,served as External Director and member of the Audit and Supervisory Committee of Takeda from June 2016 to June 2019. He was appointed External Director who is not a member of the Audit and Supervisory Committee of Takeda in June 2019. He currently also serves as Global Healthcare Advisor, President of K8 Global Pte. Ltd., External Director of Novo Holdings A/S and External Director of Rani Therapeutics. Mr. Butel previously served as President, International, Corporate Vice President and Operating Committee Member of Baxter International Inc. and has held leadership positions at Medtronic, Inc., Johnson & Johnson, Becton, Dickinson and Company and Nippon Becton Dickinson Company, Ltd. - Jean Luc Butel，2016年6月至2019年6月担任Takeda的外部董事和审计和监督委员会成员。他于2019年6月被任命为外部董事，不是Takeda的审计和监督委员会成员。他有提供肾脏和医院产品组合的医疗保健公司百特国际公司的职位：国际总裁（2015年1月至2015年6月）；公司运营总监，公司副总裁兼国际总裁（2012年2月） （2014年12月）。医疗技术领域的全球领导者美敦力公司的职位：公司官员，执行委员会成员，执行副总裁；国际集团总裁（2011年1月至2012年1月）；美敦力国际公司执行官，执行委员会委员，高级副总裁兼总裁（2008年5月至2010年12月）；美敦力公司行政总监，执行委员会委员，高级副总裁兼总裁亚太地区（2003年8月至2008年4月）。他在加入美敦力公司之前，在1991年到1999年担任过迪金森公司各种各样的领导角色后，担任独立技术、强生公司总裁。
- Jean Luc Butel,served as External Director and member of the Audit and Supervisory Committee of Takeda from June 2016 to June 2019. He was appointed External Director who is not a member of the Audit and Supervisory Committee of Takeda in June 2019. He currently also serves as Global Healthcare Advisor, President of K8 Global Pte. Ltd., External Director of Novo Holdings A/S and External Director of Rani Therapeutics. Mr. Butel previously served as President, International, Corporate Vice President and Operating Committee Member of Baxter International Inc. and has held leadership positions at Medtronic, Inc., Johnson & Johnson, Becton, Dickinson and Company and Nippon Becton Dickinson Company, Ltd.
- Jeffrey R. Balser
-
Jeffrey R. Balser，范德比尔特大学医学中心研究副校长2004年1月至2008年10月。范德比尔特大学医学中心卫生事务副校长（2009年6月至2016年4月）。范德比尔特大学医学院院长（2008年10月至今）。范德比尔特大学校长兼首席执行官医疗中心（2016年5月至今）。
Jeffrey R. Balser,Associate Vice Chancellor for Research, Vanderbilt University Medical Center January 2004-October 2008.Vice Chancellor for Health Affairs, Vanderbilt University Medical Center (June 2009-April 2016).Dean, Vanderbilt University School of Medicine (October 2008-present).President and Chief Executive Officer of Vanderbilt University Medical Center (May 2016-present). - Jeffrey R. Balser，范德比尔特大学医学中心研究副校长2004年1月至2008年10月。范德比尔特大学医学中心卫生事务副校长（2009年6月至2016年4月）。范德比尔特大学医学院院长（2008年10月至今）。范德比尔特大学校长兼首席执行官医疗中心（2016年5月至今）。
- Jeffrey R. Balser,Associate Vice Chancellor for Research, Vanderbilt University Medical Center January 2004-October 2008.Vice Chancellor for Health Affairs, Vanderbilt University Medical Center (June 2009-April 2016).Dean, Vanderbilt University School of Medicine (October 2008-present).President and Chief Executive Officer of Vanderbilt University Medical Center (May 2016-present).
- Anat Ashkenazi
-
暂无中文简介
Anat Ashkenazi,Chief Financial Officer, Lilly Oncology October 2013-April 2015.Vice President, Finance and Chief Financial Officer, Lilly Diabetes and Lilly Global Manufacturing and Quality (April 2015-September 2016).Senior Vice President, Controller and Chief Financial Officer, Lilly Research Labs (September 2016-present). -
暂无中文简介
- Anat Ashkenazi,Chief Financial Officer, Lilly Oncology October 2013-April 2015.Vice President, Finance and Chief Financial Officer, Lilly Diabetes and Lilly Global Manufacturing and Quality (April 2015-September 2016).Senior Vice President, Controller and Chief Financial Officer, Lilly Research Labs (September 2016-present).
- Phillip Febbo
-
Phillip Febbo Il Illumina，Inc。首席医疗官（2018年3月至今）。 Genomic Health，Inc。首席医学官（2013年-2018年3月）。 加利福尼亚大学旧金山分校医学与泌尿外科教授（2010年至2013年）。 美国医学遗传学和基因组学基金会董事会成员（2018年至今）。
Phillip Febbo,Service on the board of directors of the American College of Medical Genetics and Genomics Foundation 2018-2019.Professor of Medicine and Urology at the University of California, San Francisco (UCSF) (2010-2013).Chief Medical Officer, Genomic Health, Inc. (2013-March 2018).Chief Medical Officer, Illumina, Inc. (March 2018-present). - Phillip Febbo Il Illumina，Inc。首席医疗官（2018年3月至今）。 Genomic Health，Inc。首席医学官（2013年-2018年3月）。 加利福尼亚大学旧金山分校医学与泌尿外科教授（2010年至2013年）。 美国医学遗传学和基因组学基金会董事会成员（2018年至今）。
- Phillip Febbo,Service on the board of directors of the American College of Medical Genetics and Genomics Foundation 2018-2019.Professor of Medicine and Urology at the University of California, San Francisco (UCSF) (2010-2013).Chief Medical Officer, Genomic Health, Inc. (2013-March 2018).Chief Medical Officer, Illumina, Inc. (March 2018-present).
- Michelle M. Le Beau
-
Michelle M. Le Beau在芝加哥大学的职位：Arthur和Marian Edelstein医学教授，血液学/肿瘤学专业1986年至今。 芝加哥大学医学综合癌症中心主任，2004年至今。 芝加哥大学医学癌症委员会董事会成员（2012年至今）。 癌症细胞遗传学实验室主任（1986年至今）。
Michelle M. Le Beau,Positions at the University of Chicago,Arthur and Marian Edelstein Professor of Medicine, Section of Hematology/Oncology 1986-present.Director, University of Chicago Medicine Comprehensive Cancer Center (2004-present).Board Member of the University of Chicago Medicine Cancer Council (2012-present).Director, Cancer Cytogenetics Laboratory (1986-present). - Michelle M. Le Beau在芝加哥大学的职位：Arthur和Marian Edelstein医学教授，血液学/肿瘤学专业1986年至今。 芝加哥大学医学综合癌症中心主任，2004年至今。 芝加哥大学医学癌症委员会董事会成员（2012年至今）。 癌症细胞遗传学实验室主任（1986年至今）。
- Michelle M. Le Beau,Positions at the University of Chicago,Arthur and Marian Edelstein Professor of Medicine, Section of Hematology/Oncology 1986-present.Director, University of Chicago Medicine Comprehensive Cancer Center (2004-present).Board Member of the University of Chicago Medicine Cancer Council (2012-present).Director, Cancer Cytogenetics Laboratory (1986-present).
- Anat Ashkenazi
-
Anat Ashkenazi，自2021年起担任高级副总裁兼首席财务官。在此之前，Ashkenazi女士在礼来担任过各种领导职务，包括礼来研究实验室的高级副总裁、财务总监和首席财务官，以及Lilly Diabetes和礼来全球制造和质量公司的副总裁、财务总监和首席财务官。Ashkenazi女士在礼来服务了19年。
Anat Ashkenazi,held various leadership roles with Lilly, including senior vice president, controller and chief financial officer, Lilly Research Laboratories, and vice president, finance and chief financial officer, Lilly Diabetes and Lilly global manufacturing and quality. Ms. Ashkenazi has 22 years of service with Lilly. - Anat Ashkenazi，自2021年起担任高级副总裁兼首席财务官。在此之前，Ashkenazi女士在礼来担任过各种领导职务，包括礼来研究实验室的高级副总裁、财务总监和首席财务官，以及Lilly Diabetes和礼来全球制造和质量公司的副总裁、财务总监和首席财务官。Ashkenazi女士在礼来服务了19年。
- Anat Ashkenazi,held various leadership roles with Lilly, including senior vice president, controller and chief financial officer, Lilly Research Laboratories, and vice president, finance and chief financial officer, Lilly Diabetes and Lilly global manufacturing and quality. Ms. Ashkenazi has 22 years of service with Lilly.
- Judy Bruner
-
Judy Bruner，2009年1月以来曾担任董事。于2002年6月至2004年7月在SanDisk Corporation董事会任职。2004年6月以来，布鲁纳一直是美国晟碟公司的执行副总裁，首席财务官管理，一家闪存产品的供应商。从1999年9月到2004年6月，布鲁纳女士担任奔迈公司的高级副总裁兼首席财务官，一家手持计算和通信解决方案供应商。在加入奔迈之前，布鲁纳女士在3com公司，Ridge电脑公司和惠普公司担任财务管理职位。布鲁纳女士拥有洛杉矶加州大学经济学学士学位和圣克拉拉大学的工商管理硕士学位。
Judy Bruner,has served on the Board of Directors since May 2021. She served as the Executive Vice President, Administration and Chief Financial Officer of SanDisk Corp, a supplier of flash storage products, from June 2004 until its acquisition by Western Digital in May 2016. Ms. Bruner was Senior Vice President and Chief Financial Officer of Palm, Inc., a provider of handheld computing and communications solutions, from September 1999 until June 2004. Prior to that, she held financial management positions at 3Com Corporation, Ridge Computers and Hewlett-Packard Company. Ms. Bruner has served as a member of the boards of directors of Applied Materials, Inc., a publicly traded semiconductor equipment manufacturer, since July 2016, Rapid7, Inc., a security data and analytics solutions provider, since October 2016, and Seagate Technology Holdings plc, a publicly traded provider of storage solutions, since January 2018. She previously served on the boards of directors of Brocade Communications Systems, Inc. from January 2009 to November 2017 and Varian Medical Systems, Inc. from August 2016 to April 2021. - Judy Bruner，2009年1月以来曾担任董事。于2002年6月至2004年7月在SanDisk Corporation董事会任职。2004年6月以来，布鲁纳一直是美国晟碟公司的执行副总裁，首席财务官管理，一家闪存产品的供应商。从1999年9月到2004年6月，布鲁纳女士担任奔迈公司的高级副总裁兼首席财务官，一家手持计算和通信解决方案供应商。在加入奔迈之前，布鲁纳女士在3com公司，Ridge电脑公司和惠普公司担任财务管理职位。布鲁纳女士拥有洛杉矶加州大学经济学学士学位和圣克拉拉大学的工商管理硕士学位。
- Judy Bruner,has served on the Board of Directors since May 2021. She served as the Executive Vice President, Administration and Chief Financial Officer of SanDisk Corp, a supplier of flash storage products, from June 2004 until its acquisition by Western Digital in May 2016. Ms. Bruner was Senior Vice President and Chief Financial Officer of Palm, Inc., a provider of handheld computing and communications solutions, from September 1999 until June 2004. Prior to that, she held financial management positions at 3Com Corporation, Ridge Computers and Hewlett-Packard Company. Ms. Bruner has served as a member of the boards of directors of Applied Materials, Inc., a publicly traded semiconductor equipment manufacturer, since July 2016, Rapid7, Inc., a security data and analytics solutions provider, since October 2016, and Seagate Technology Holdings plc, a publicly traded provider of storage solutions, since January 2018. She previously served on the boards of directors of Brocade Communications Systems, Inc. from January 2009 to November 2017 and Varian Medical Systems, Inc. from August 2016 to April 2021.
- R. Andrew Eckert
-
R. Andrew Eckert，于2016年9月被任命到碧迪医疗器械有限公司董事会。自2004年以来担任瓦里安医疗系统公司董事。自2011年1月起担任CRC保健公司（药物滥用治疗和青春期青少年服务的提供商）的的行政总裁。此前，从2009年10月到2011年1月，担任管理交响乐团科技集团（一家私募股权公司）的董事。从2005年10月至2009年5月担任Eclipsys公司（一个医疗信息管理软件供应商）的总裁兼行政总裁。从2004年到2005年担任SumTotal Systems公司（企业软件供应商）的行政总裁。从2002年到2004年担任Docent公司（被SumTotal Systems公司收购的一个企业软件供应商）的行政总裁。此前，1997年至2001年担任ADAC实验室（医疗影像公司）的董事长及行政总裁。在过去五年中曾担任Eclipsys公司的董事会。
R. Andrew Eckert currently serves as a Senior Advisor to Permira, a global private equity firm. He served as Chief Executive Officer of Zelis Inc., a provider of healthcare cost management and payments solutions, from 2020 to 2021.Served as President and Chief Executive Officer of Acelity L.P. Inc., a global wound care company, from 2017 until the sale of the company in October 2019.Served as the Chief Executive Officer of Valence Health, Inc., a healthcare information technology and services company, from 2015 until its sale in 2016.Previously served as Chief Executive Officer of TriZetto Corporation, a payer technology solutions firm, and Chief Executive Officer of CRC Health Group, a provider of specialized behavioral healthcare services.Also previously served as Chief Executive Officer of Eclipsys, a healthcare provider technology firm, and ADAC Laboratories, a medical capital equipment company. - R. Andrew Eckert，于2016年9月被任命到碧迪医疗器械有限公司董事会。自2004年以来担任瓦里安医疗系统公司董事。自2011年1月起担任CRC保健公司（药物滥用治疗和青春期青少年服务的提供商）的的行政总裁。此前，从2009年10月到2011年1月，担任管理交响乐团科技集团（一家私募股权公司）的董事。从2005年10月至2009年5月担任Eclipsys公司（一个医疗信息管理软件供应商）的总裁兼行政总裁。从2004年到2005年担任SumTotal Systems公司（企业软件供应商）的行政总裁。从2002年到2004年担任Docent公司（被SumTotal Systems公司收购的一个企业软件供应商）的行政总裁。此前，1997年至2001年担任ADAC实验室（医疗影像公司）的董事长及行政总裁。在过去五年中曾担任Eclipsys公司的董事会。
- R. Andrew Eckert currently serves as a Senior Advisor to Permira, a global private equity firm. He served as Chief Executive Officer of Zelis Inc., a provider of healthcare cost management and payments solutions, from 2020 to 2021.Served as President and Chief Executive Officer of Acelity L.P. Inc., a global wound care company, from 2017 until the sale of the company in October 2019.Served as the Chief Executive Officer of Valence Health, Inc., a healthcare information technology and services company, from 2015 until its sale in 2016.Previously served as Chief Executive Officer of TriZetto Corporation, a payer technology solutions firm, and Chief Executive Officer of CRC Health Group, a provider of specialized behavioral healthcare services.Also previously served as Chief Executive Officer of Eclipsys, a healthcare provider technology firm, and ADAC Laboratories, a medical capital equipment company.
- David J. Illingworth
-
David J. Illingworth从2011年8月开始担任董事。目前已退休。从2007年7月到2011年4月，他是Smith & Nephew plc的前首席执行官，这是一家全球医疗设备生产公司。从2002年到2007年7月，担任Smith & Nephew的首席运营官兼部门总裁。加入Smith & Nephew前，他担任多个高级管理职位，包括XL Vision, Inc.的总裁， VidaMed, Inc.的董事会主席兼首席执行官，担任Nellcor Puritan Bennett LLC的总裁，并GE医疗系统（ GE Medical Systems）亚太地区的常务董事。Illingworth先生在过去5年担任Smith & Nephew的董事。
David J. Illingworth,Chief Operating Officer and Division President 2002-July 2007.Chief Executive Officer (July 2007-April 2011). - David J. Illingworth从2011年8月开始担任董事。目前已退休。从2007年7月到2011年4月，他是Smith & Nephew plc的前首席执行官，这是一家全球医疗设备生产公司。从2002年到2007年7月，担任Smith & Nephew的首席运营官兼部门总裁。加入Smith & Nephew前，他担任多个高级管理职位，包括XL Vision, Inc.的总裁， VidaMed, Inc.的董事会主席兼首席执行官，担任Nellcor Puritan Bennett LLC的总裁，并GE医疗系统（ GE Medical Systems）亚太地区的常务董事。Illingworth先生在过去5年担任Smith & Nephew的董事。
- David J. Illingworth,Chief Operating Officer and Division President 2002-July 2007.Chief Executive Officer (July 2007-April 2011).
- Regina E. Dugan
-
Regina E. Dugan自2013年12月起担任董事。自2012年3月起在谷歌的摩托罗拉移动有限责任公司（移动技术公司，2012年5月由谷歌收购）担任负责先进技术和产品的高级副总裁。此前，从2009年7月到2012年3月担任美国国防部高级研究计划局（DARPA，一个美国国防部的研究开发组织）的董事，从2005年到2009年7月担任RedXDefense有限责任公司（一个安全解决方案的公司）的共同创办人、总裁兼首席执行官，从2001年至2009年7月担任杜根风险投资公司（投资公司）的共同创办人、总裁兼首席执行官，现仍担任无表决权的合作伙伴。
Regina E. Dugan,has served as the President and Chief Executive Officer of Wellcome Leap Inc., a U.S. non-profit organization supporting discovery and innovation for the benefit of human health, since April 2020. Prior to that, Dr. Dugan served as Vice President, Engineering at then-Facebook Inc.'s Building 8 from 2016 to 2018, and Vice President of Engineering at then-Google Inc.'s Advance Technology and Projects from 2012 to 2016. From 2009 to 2012, Dr. Dugan served as the 19th Director of the Defense Advanced Research Projects Agency ("DARPA"), and was the first woman to lead the agency. Prior to that, Dr. Dugan served in various private high tech commercial roles and public roles in the US Department of Defense and the National Aeronautics and Space Administration. - Regina E. Dugan自2013年12月起担任董事。自2012年3月起在谷歌的摩托罗拉移动有限责任公司（移动技术公司，2012年5月由谷歌收购）担任负责先进技术和产品的高级副总裁。此前，从2009年7月到2012年3月担任美国国防部高级研究计划局（DARPA，一个美国国防部的研究开发组织）的董事，从2005年到2009年7月担任RedXDefense有限责任公司（一个安全解决方案的公司）的共同创办人、总裁兼首席执行官，从2001年至2009年7月担任杜根风险投资公司（投资公司）的共同创办人、总裁兼首席执行官，现仍担任无表决权的合作伙伴。
- Regina E. Dugan,has served as the President and Chief Executive Officer of Wellcome Leap Inc., a U.S. non-profit organization supporting discovery and innovation for the benefit of human health, since April 2020. Prior to that, Dr. Dugan served as Vice President, Engineering at then-Facebook Inc.'s Building 8 from 2016 to 2018, and Vice President of Engineering at then-Google Inc.'s Advance Technology and Projects from 2012 to 2016. From 2009 to 2012, Dr. Dugan served as the 19th Director of the Defense Advanced Research Projects Agency ("DARPA"), and was the first woman to lead the agency. Prior to that, Dr. Dugan served in various private high tech commercial roles and public roles in the US Department of Defense and the National Aeronautics and Space Administration.
高管简历
中英对照 | 中文 | 英文- Dow R. Wilson
Dow R. Wilson，自2012年9月起担任瓦里安医疗系统公司董事，自2012年9月起担任总裁兼首席执行官。2011年10月至2012年9月担任执行副总裁兼首席营运官，2005年8月至2011年9月担任公司负责肿瘤系统的执行副总裁和总裁。2005年1月至2005年8月，担任公司负责肿瘤系统的副总裁和总裁。2005年1月加入瓦里安医疗系统公司之前，曾在通用电气（一家多元化的工业公司）中担任高级管理职务。是萨巴软件公司（电子学习软件供应商）的董事会成员。
Dow R. Wilson,was appointed to serve on the Board of Directors of Siemens Healthineers AG in February 2023. He retired as President and Chief Executive Officer of Varian Medical Systems, Inc. in April 2021, a position he held since September 2012. Prior to that, Mr. Wilson served in various capacities with Varian, including Executive Vice President and Chief Operating Officer from October 2011 to September 2012 and Vice President Varian Medical and President of Varian Medical Oncology Systems business from January 2005 to September 2011. Prior to joining Varian Medical in 2005, Mr. Wilson held various senior management positions with GE Healthcare, a diversified industrial company.- Dow R. Wilson，自2012年9月起担任瓦里安医疗系统公司董事，自2012年9月起担任总裁兼首席执行官。2011年10月至2012年9月担任执行副总裁兼首席营运官，2005年8月至2011年9月担任公司负责肿瘤系统的执行副总裁和总裁。2005年1月至2005年8月，担任公司负责肿瘤系统的副总裁和总裁。2005年1月加入瓦里安医疗系统公司之前，曾在通用电气（一家多元化的工业公司）中担任高级管理职务。是萨巴软件公司（电子学习软件供应商）的董事会成员。
- Dow R. Wilson,was appointed to serve on the Board of Directors of Siemens Healthineers AG in February 2023. He retired as President and Chief Executive Officer of Varian Medical Systems, Inc. in April 2021, a position he held since September 2012. Prior to that, Mr. Wilson served in various capacities with Varian, including Executive Vice President and Chief Operating Officer from October 2011 to September 2012 and Vice President Varian Medical and President of Varian Medical Oncology Systems business from January 2005 to September 2011. Prior to joining Varian Medical in 2005, Mr. Wilson held various senior management positions with GE Healthcare, a diversified industrial company.
- Christopher A. Toth
Christopher A. Toth自2018年10月起被任命为肿瘤学系统总裁。托斯先生于2001年加入瓦里安（Varian），在其任职期间曾担任多个跨职能职位和执行职务。在被任命为肿瘤系统总裁之前，Toth先生于2017年1月至2018年9月担任全球商业和现场运营总裁，负责肿瘤系统和Proton Solutions的全球销售战略和执行。此外，Toth先生还负责肿瘤学系统业务的全球现场服务，应用培训，市场准入和区域营销。从2014年9月至2017年1月，托斯先生（Toth）担任美洲肿瘤系统总裁，从2011年4月至2014年9月担任全球营销副总裁。托斯先生拥有学士学位俄勒冈大学隆德奎斯特商学院（Lundquist College of Business）获得工商管理学位，主修市场营销。
Christopher A. Toth was appointed President and Chief Operating Officer in October 2020. Mr. Toth served as President of Oncology Systems from October 2018 to October 2020. Mr. Toth joined Varian in 2001 and has held multiple cross-functional roles and executive positions during his tenure with the company. Prior to his appointment as President of Oncology Systems, Mr. Toth served as President of Global Commercial and Field Operations from January 2017 to September 2018 where he was responsible for global sales strategy and execution for Oncology Systems and Proton Solutions. Additionally, in this role, Mr. Toth was responsible for global field service, applications training, market access and regional marketing for the Oncology Systems business. From September 2014 to January 2017 Mr. Toth was President, Oncology Systems Americas and from April 2011 to September 2014 Vice President, Global Marketing. Mr. Toth holds a B.A. degree in Business Administration with a concentration in Marketing from the Lundquist College of Business at the University of Oregon.- Christopher A. Toth自2018年10月起被任命为肿瘤学系统总裁。托斯先生于2001年加入瓦里安（Varian），在其任职期间曾担任多个跨职能职位和执行职务。在被任命为肿瘤系统总裁之前，Toth先生于2017年1月至2018年9月担任全球商业和现场运营总裁，负责肿瘤系统和Proton Solutions的全球销售战略和执行。此外，Toth先生还负责肿瘤学系统业务的全球现场服务，应用培训，市场准入和区域营销。从2014年9月至2017年1月，托斯先生（Toth）担任美洲肿瘤系统总裁，从2011年4月至2014年9月担任全球营销副总裁。托斯先生拥有学士学位俄勒冈大学隆德奎斯特商学院（Lundquist College of Business）获得工商管理学位，主修市场营销。
- Christopher A. Toth was appointed President and Chief Operating Officer in October 2020. Mr. Toth served as President of Oncology Systems from October 2018 to October 2020. Mr. Toth joined Varian in 2001 and has held multiple cross-functional roles and executive positions during his tenure with the company. Prior to his appointment as President of Oncology Systems, Mr. Toth served as President of Global Commercial and Field Operations from January 2017 to September 2018 where he was responsible for global sales strategy and execution for Oncology Systems and Proton Solutions. Additionally, in this role, Mr. Toth was responsible for global field service, applications training, market access and regional marketing for the Oncology Systems business. From September 2014 to January 2017 Mr. Toth was President, Oncology Systems Americas and from April 2011 to September 2014 Vice President, Global Marketing. Mr. Toth holds a B.A. degree in Business Administration with a concentration in Marketing from the Lundquist College of Business at the University of Oregon.
- J. Michael Bruff
J. Michael Bruff自2021年3月起担任LifeStance Health Group, Inc.的首席财务官。J. Michael Bruff目前担任财务与投资者关系高级副总裁，自2019年12月1日起接替Bischoping先生为首席财务官。Bruff先生于2017年8月至2018年2月担任投资者关系副总裁，从2018年2月至今担任财务和投资者关系高级副总裁。Bruff先生在Dell Technologies担任了19年的国内和国际职务，最近担任北美销售策略与计划高级副总裁。在此之前，他曾担任戴尔亚太及日本商业业务高级副总裁兼首席财务官，以及大中华区商业业务副总裁兼首席财务官。他还曾在商业金融，财务计划和分析，内部审计和企业解决方案集团财务部门担任过其他几个财务领导职务。此外，Bruff先生曾担任CA，Inc。全球服务会计和财务副总裁，并在MCI Telecommunications中担任过各种财务和报告职务。
J. Michael Bruff has served as our Chief Financial Officer since March 2021. Mr. Bruff has 30 years of professional experience in a variety of industries including medical technology, computer hardware and software, enterprise software, telecommunications, and public accounting. Before joining LifeStance, Mr. Bruff served as Chief Financial Officer of Varian Medical Systems, an innovative cancer care solutions company serving clinical partners globally. Prior to that, Mr. Bruff worked for Dell Technologies for 19 years serving in several domestic and international roles across finance and commercial business functions, most recently as business unit Chief Financial Officer of Dell's Asia-Pacific and Japan Commercial Business and Senior Vice President of North American Sales Strategy and Planning. He also held leadership roles in commercial finance, financial planning and analysis, internal audit, and product development finance. In addition, Mr. Bruff was Vice President, Global Services Accounting and Finance at CA, Inc. and held a variety of finance and reporting roles at MCI Telecommunications from 1995 to 1997 after starting his career at Deloitte & Touche. Mr. Bruff holds a Bachelor of Science in accounting and a Bachelor of Arts in economics from the University of Maryland.- J. Michael Bruff自2021年3月起担任LifeStance Health Group, Inc.的首席财务官。J. Michael Bruff目前担任财务与投资者关系高级副总裁，自2019年12月1日起接替Bischoping先生为首席财务官。Bruff先生于2017年8月至2018年2月担任投资者关系副总裁，从2018年2月至今担任财务和投资者关系高级副总裁。Bruff先生在Dell Technologies担任了19年的国内和国际职务，最近担任北美销售策略与计划高级副总裁。在此之前，他曾担任戴尔亚太及日本商业业务高级副总裁兼首席财务官，以及大中华区商业业务副总裁兼首席财务官。他还曾在商业金融，财务计划和分析，内部审计和企业解决方案集团财务部门担任过其他几个财务领导职务。此外，Bruff先生曾担任CA，Inc。全球服务会计和财务副总裁，并在MCI Telecommunications中担任过各种财务和报告职务。
- J. Michael Bruff has served as our Chief Financial Officer since March 2021. Mr. Bruff has 30 years of professional experience in a variety of industries including medical technology, computer hardware and software, enterprise software, telecommunications, and public accounting. Before joining LifeStance, Mr. Bruff served as Chief Financial Officer of Varian Medical Systems, an innovative cancer care solutions company serving clinical partners globally. Prior to that, Mr. Bruff worked for Dell Technologies for 19 years serving in several domestic and international roles across finance and commercial business functions, most recently as business unit Chief Financial Officer of Dell's Asia-Pacific and Japan Commercial Business and Senior Vice President of North American Sales Strategy and Planning. He also held leadership roles in commercial finance, financial planning and analysis, internal audit, and product development finance. In addition, Mr. Bruff was Vice President, Global Services Accounting and Finance at CA, Inc. and held a variety of finance and reporting roles at MCI Telecommunications from 1995 to 1997 after starting his career at Deloitte & Touche. Mr. Bruff holds a Bachelor of Science in accounting and a Bachelor of Arts in economics from the University of Maryland.
- Kevin O'Reilly
Kevin O'Reilly于2020年10月被任命为Varian肿瘤系统高级副总裁兼总裁。在此任命之前，他于2019年4月至2020年10月担任全球运营高级副总裁，并于2020年4月至2006年4月担任EMEIA临时总裁。2016年2月至2019年4月担任亚太地区总裁，2014年至2016年担任战略与业务发展副总裁，2012年至2014年担任产品营销高级总监，2009年至2012年担任服务营销和全球出版物高级总监。加入Varian之前，O'Reilly先生曾在RPO，Inc.和Photon Dynamics担任执行职务。他拥有都柏林工业大学的电子工程学士学位。
Kevin O'Reilly was appointed Senior Vice President and President, Varian Oncology Systems in October 2020. Prior to this appointment, he served as Senior Vice President, Global Operations, between April 2019 and October 2020 as interim President of EMEIA between April 2020 and October 2020 President, Asia Pacific between February 2016 and April 2019 VP Strategy and Business Development between 2014 and 2016 Senior Director, Product Marketing between 2012 and 2014 and as Senior Director, Services Marketing and Global Publications between 2009 and 2012. Prior to joining Varian, Mr. O'Reilly held executive positions at RPO, Inc., and Photon Dynamics. He holds a BS in Electronic Engineering from Technological University Dublin.- Kevin O'Reilly于2020年10月被任命为Varian肿瘤系统高级副总裁兼总裁。在此任命之前，他于2019年4月至2020年10月担任全球运营高级副总裁，并于2020年4月至2006年4月担任EMEIA临时总裁。2016年2月至2019年4月担任亚太地区总裁，2014年至2016年担任战略与业务发展副总裁，2012年至2014年担任产品营销高级总监，2009年至2012年担任服务营销和全球出版物高级总监。加入Varian之前，O'Reilly先生曾在RPO，Inc.和Photon Dynamics担任执行职务。他拥有都柏林工业大学的电子工程学士学位。
- Kevin O'Reilly was appointed Senior Vice President and President, Varian Oncology Systems in October 2020. Prior to this appointment, he served as Senior Vice President, Global Operations, between April 2019 and October 2020 as interim President of EMEIA between April 2020 and October 2020 President, Asia Pacific between February 2016 and April 2019 VP Strategy and Business Development between 2014 and 2016 Senior Director, Product Marketing between 2012 and 2014 and as Senior Director, Services Marketing and Global Publications between 2009 and 2012. Prior to joining Varian, Mr. O'Reilly held executive positions at RPO, Inc., and Photon Dynamics. He holds a BS in Electronic Engineering from Technological University Dublin.
- Michael Hutchinson
Michael Hutchinson于2020年6月被任命为高级副总裁，首席法律官兼公司秘书。在加入公司之前，Hutchinson先生在Stryker工作了12年，从2019年到2020年，他担任董事长兼首席执行官的副总裁兼顾问。从2013年至2019年担任法律总顾问，副总裁兼首席法律官，在2008年至2013年之间担任骨科首席法律顾问副总法律顾问。在加入Stryker之前，Hutchinson先生曾在华盛顿特区地区多家律师事务所工作。Hutchinson先生拥有乔治华盛顿大学法学院的法学博士学位和文学士学位和克拉克大学学位。
Michael Hutchinson was appointed Senior Vice President, Chief Legal Officer and Corporate Secretary in June 2020. Prior to joining the Company, Mr. Hutchinson was with Stryker for 12 years, where he served as Vice President and Advisor to the Chairman and CEO from 2019 to 2020 General Counsel, Vice President and Chief Legal Officer from 2013 to 2019 and Deputy General Counsel, Chief Legal Counsel Orthopaedics Group between 2008 and 2013. Prior to joining Stryker, Mr. Hutchinson worked for several law firms and as an in-house attorney in the Washington, D.C. area. Mr. Hutchinson holds a J.D. degree from The George Washington University Law School and a B.A. degree from Clark University.- Michael Hutchinson于2020年6月被任命为高级副总裁，首席法律官兼公司秘书。在加入公司之前，Hutchinson先生在Stryker工作了12年，从2019年到2020年，他担任董事长兼首席执行官的副总裁兼顾问。从2013年至2019年担任法律总顾问，副总裁兼首席法律官，在2008年至2013年之间担任骨科首席法律顾问副总法律顾问。在加入Stryker之前，Hutchinson先生曾在华盛顿特区地区多家律师事务所工作。Hutchinson先生拥有乔治华盛顿大学法学院的法学博士学位和文学士学位和克拉克大学学位。
- Michael Hutchinson was appointed Senior Vice President, Chief Legal Officer and Corporate Secretary in June 2020. Prior to joining the Company, Mr. Hutchinson was with Stryker for 12 years, where he served as Vice President and Advisor to the Chairman and CEO from 2019 to 2020 General Counsel, Vice President and Chief Legal Officer from 2013 to 2019 and Deputy General Counsel, Chief Legal Counsel Orthopaedics Group between 2008 and 2013. Prior to joining Stryker, Mr. Hutchinson worked for several law firms and as an in-house attorney in the Washington, D.C. area. Mr. Hutchinson holds a J.D. degree from The George Washington University Law School and a B.A. degree from Clark University.
- Kolleen T. Kennedy
Kolleen T. Kennedy被任命为负责肿瘤系统的高级副总裁及总裁，2011年10月起生效。从2006年1月至2011年9月担任负责肿瘤系统客户服务和支持的副总裁。在此之前，从2004年9月至2006年1月担任公司负责肿瘤系统市场营销、产品管理和工程的副总裁。自1997年加入公司到成为副总裁之前，曾担任多个营销管理职位。在韦恩州立大学获得放射肿瘤学学士学位和心理学学士学位，在科罗拉多大学获得医学物理硕士学位。
Kolleen T. Kennedy was appointed President of Proton Solutions and Chief Growth Officer effective October 2018. Ms. Kennedy served as Executive Vice President and President, Oncology Systems from September 2014 to September 2018 and was Senior Vice President and President, Oncology Systems from October 2011 to September 2014. From January 2006 through September 2011 Ms. Kennedy served as Vice President, Oncology Systems Customer Service and Support. Prior to that, Ms. Kennedy was the Company’s Vice President, Oncology Systems Marketing, Product Management and Engineering from September 2004 to January 2006. Prior to becoming Vice President, Ms. Kennedy served in various marketing management positions since she joined the Company in 1997. Ms. Kennedy holds a B.S. degree in Radiation Oncology and a B.S. degree in Psychology, both from Wayne State University, as well as an M.S. degree in Medical Physics from the University of Colorado.- Kolleen T. Kennedy被任命为负责肿瘤系统的高级副总裁及总裁，2011年10月起生效。从2006年1月至2011年9月担任负责肿瘤系统客户服务和支持的副总裁。在此之前，从2004年9月至2006年1月担任公司负责肿瘤系统市场营销、产品管理和工程的副总裁。自1997年加入公司到成为副总裁之前，曾担任多个营销管理职位。在韦恩州立大学获得放射肿瘤学学士学位和心理学学士学位，在科罗拉多大学获得医学物理硕士学位。
- Kolleen T. Kennedy was appointed President of Proton Solutions and Chief Growth Officer effective October 2018. Ms. Kennedy served as Executive Vice President and President, Oncology Systems from September 2014 to September 2018 and was Senior Vice President and President, Oncology Systems from October 2011 to September 2014. From January 2006 through September 2011 Ms. Kennedy served as Vice President, Oncology Systems Customer Service and Support. Prior to that, Ms. Kennedy was the Company’s Vice President, Oncology Systems Marketing, Product Management and Engineering from September 2004 to January 2006. Prior to becoming Vice President, Ms. Kennedy served in various marketing management positions since she joined the Company in 1997. Ms. Kennedy holds a B.S. degree in Radiation Oncology and a B.S. degree in Psychology, both from Wayne State University, as well as an M.S. degree in Medical Physics from the University of Colorado.